JP2016525136A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525136A5
JP2016525136A5 JP2016528481A JP2016528481A JP2016525136A5 JP 2016525136 A5 JP2016525136 A5 JP 2016525136A5 JP 2016528481 A JP2016528481 A JP 2016528481A JP 2016528481 A JP2016528481 A JP 2016528481A JP 2016525136 A5 JP2016525136 A5 JP 2016525136A5
Authority
JP
Japan
Prior art keywords
formula
represents hydrogen
methyl
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016528481A
Other languages
English (en)
Japanese (ja)
Other versions
JP6410819B2 (ja
JP2016525136A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/065608 external-priority patent/WO2015011087A1/de
Publication of JP2016525136A publication Critical patent/JP2016525136A/ja
Publication of JP2016525136A5 publication Critical patent/JP2016525136A5/ja
Application granted granted Critical
Publication of JP6410819B2 publication Critical patent/JP6410819B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016528481A 2013-07-23 2014-07-21 置換オキソピリジン誘導体および第XIa因子/血漿としてのその使用 Expired - Fee Related JP6410819B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13177605 2013-07-23
EP13177605.6 2013-07-23
PCT/EP2014/065608 WO2015011087A1 (de) 2013-07-23 2014-07-21 Substituierte oxopyridin-derivate und ihre verwendung als faktor xia / plasma

Publications (3)

Publication Number Publication Date
JP2016525136A JP2016525136A (ja) 2016-08-22
JP2016525136A5 true JP2016525136A5 (OSRAM) 2017-08-17
JP6410819B2 JP6410819B2 (ja) 2018-10-24

Family

ID=48803476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016528481A Expired - Fee Related JP6410819B2 (ja) 2013-07-23 2014-07-21 置換オキソピリジン誘導体および第XIa因子/血漿としてのその使用

Country Status (7)

Country Link
US (2) US9475809B2 (OSRAM)
EP (1) EP3024822B1 (OSRAM)
JP (1) JP6410819B2 (OSRAM)
CN (1) CN105555767B (OSRAM)
CA (1) CA2918814C (OSRAM)
ES (1) ES2633248T3 (OSRAM)
WO (1) WO2015011087A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
WO2015011087A1 (de) * 2013-07-23 2015-01-29 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate und ihre verwendung als faktor xia / plasma
NO2760821T3 (OSRAM) 2014-01-31 2018-03-10
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
ES2712886T3 (es) 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
ES2694189T3 (es) 2014-09-24 2018-12-18 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
WO2016046159A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197872B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen
EP3197896B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (de) 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US10344039B2 (en) 2015-10-29 2019-07-09 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use
TW201808908A (zh) 2016-08-22 2018-03-16 美商默沙東藥廠 因子XIa抑制劑
CN106831761B (zh) * 2016-12-14 2019-02-12 浙江工业大学 顺式四氢-1H-吡咯并[3,4-b]吡啶-2,5(3H,6H)-二酮的合成方法
PE20210165A1 (es) 2018-04-10 2021-01-26 Bayer Pharma AG Un derivado de oxopiridina sustituido
WO2020127508A1 (en) 2018-12-21 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
CN113474348A (zh) 2018-12-21 2021-10-01 拜耳公司 取代的氧代吡啶衍生物
CN110105276A (zh) * 2019-06-24 2019-08-09 红河学院 一种2-喹啉酮化合物及其制备方法
CN112778273B (zh) * 2019-11-11 2022-08-23 江西济民可信集团有限公司 环酮并吡啶酮类化合物及其制备方法和用途
CN112778277B (zh) * 2019-11-11 2024-04-02 江西济民可信集团有限公司 环酮并吡啶酮联杂芳环化合物及其制备方法和用途
CN113135929B (zh) * 2020-01-17 2024-04-19 江西济民可信集团有限公司 呋喃并吡啶酮酰胺化合物及其制备方法和用途
CN113135930B (zh) * 2020-01-17 2023-11-17 上海济煜医药科技有限公司 呋喃并吡啶酮咪唑化合物及其制备方法和用途
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
PL2489659T3 (pl) * 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7459564B2 (en) * 2005-01-13 2008-12-02 Bristol-Myers Squibb Company Substituted biaryl compounds as factor XIa inhibitors
CN101341129B (zh) * 2005-12-14 2011-12-14 布里斯托尔-迈尔斯斯奎布公司 作为因子xia抑制剂的芳基丙酰胺,芳基丙烯酰胺,芳基丙炔酰胺,或芳基甲基脲类似物
JP5342450B2 (ja) * 2006-12-15 2013-11-13 ブリストル−マイヤーズ スクイブ カンパニー 第XIa因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2009076337A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
PE20140239A1 (es) * 2010-10-07 2014-03-07 Takeda Pharmaceutical Derivados de 1,4-oxazepano
JP6137193B2 (ja) * 2011-12-21 2017-05-31 小野薬品工業株式会社 第XIa因子阻害剤としての新規ピリジノンおよびピリミジノン誘導体
WO2015011087A1 (de) * 2013-07-23 2015-01-29 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate und ihre verwendung als faktor xia / plasma

Similar Documents

Publication Publication Date Title
JP2016525136A5 (OSRAM)
JP2016515562A5 (OSRAM)
JP2018519323A5 (OSRAM)
JP2016535031A5 (OSRAM)
JP2016540742A5 (OSRAM)
JP2016507581A5 (OSRAM)
JP2015500843A5 (OSRAM)
JP2013542261A5 (OSRAM)
JP2016516043A5 (OSRAM)
CA2749048A1 (en) Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases
JP2019524883A5 (OSRAM)
JP2011528658A5 (OSRAM)
JP2015531773A5 (OSRAM)
JP2018514518A5 (OSRAM)
JP2009515988A5 (OSRAM)
JP2016506960A5 (OSRAM)
JP2014525420A5 (OSRAM)
JP2017509689A5 (OSRAM)
JP2019522055A5 (OSRAM)
JP2013510124A5 (OSRAM)
JP2016525075A5 (OSRAM)
JP2016513696A5 (OSRAM)
JP2017528496A5 (OSRAM)
JP2013540712A5 (OSRAM)
JP2016190843A5 (OSRAM)